Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent.


Journal

Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 01 05 2021
revised: 10 06 2021
accepted: 12 06 2021
pubmed: 22 7 2021
medline: 15 12 2021
entrez: 21 7 2021
Statut: ppublish

Résumé

The purpose of this study was to compare the value of contrast-enhanced computed tomography (CT) to that of magnetic resonance imaging obtained with extracellular contrast agent (ECA-MRI) for the diagnosis of a tumor capsule in hepatocellular carcinoma (HCC) using histopathologic findings as the standard of reference. This retrospective study included patients with pathologically-proven resected HCCs with available preoperative contrast-enhanced CT and ECA-MRI examinations. Two blinded radiologists independently reviewed contrast-enhanced CT and ECA-MRI examinations to assess the presence of an enhancing capsule. The histopathological analysis of resected specimens was used as reference for the diagnosis of a tumor capsule. The sensitivity and specificity of CT and ECA-MRI for the diagnosis of a tumor capsule were determined, and an intra-individual comparison of imaging modalities was performed using McNemar test. Inter-reader agreement was assessed using Kappa test. The study population included 199 patients (157 men, 42 women; mean age: 61.3 ± 13.0 [SD] years) with 210 HCCs (mean size 56.7 ± 43.7 [SD] mm). A tumor capsule was present in 157/210 (74.8%) HCCs at histopathologic analysis. Capsule enhancement was more frequently visualized on ECA-MRI (R1, 68.6%; R2, 71.9%) than on CT (R1, 44.3%, P < 0.001; R2, 47.6%, P < 0.001). The sensitivity of ECA-MRI was better for the diagnosis of histopathological tumor capsule (R1, 76.4%; R2, 79.6%; P < 0.001), while CT had a greater specificity (R1, 84.9%; R2, 83.0%; P < 0.001). Inter-reader agreement was moderate both on CT (kappa = 0.55; 95% confidence interval [CI]: 0.43-0.66) and ECA-MRI (kappa = 0.57; 95% CI: 0.45-0.70). Capsule enhancement was more frequently visualized on ECA-MRI than on CT. The sensitivity of ECA-MRI was greater than that of CT, but the specificity of CT was better than that of ECA-MRI.

Identifiants

pubmed: 34284951
pii: S2211-5684(21)00166-2
doi: 10.1016/j.diii.2021.06.004
pii:
doi:

Substances chimiques

Contrast Media 0
Gadolinium DTPA K2I13DR72L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

735-742

Informations de copyright

Copyright © 2021 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Roberto Cannella (R)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France; Section of Radiology - BiND, University Hospital "Paolo Giaccone", 90127 Palermo, Italy; Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, 90127 Palermo, Italy.

Maxime Ronot (M)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France; Université de Paris, Faculté de Médecine & INSERM U1149 "centre de recherche sur l'inflammation", CRI, F-75018 Paris, France.

Riccardo Sartoris (R)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France; Université de Paris, Faculté de Médecine & INSERM U1149 "centre de recherche sur l'inflammation", CRI, F-75018 Paris, France.

Francois Cauchy (F)

Department of HPB Surgery and Liver Transplantation, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Christian Hobeika (C)

Department of HPB Surgery and Liver Transplantation, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Aurélie Beaufrere (A)

Department of Pathology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Loïc Trapani (L)

Department of Pathology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Valérie Paradis (V)

Department of Pathology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Mohamed Bouattour (M)

Department of Digestive Oncology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Fanny Bonvalet (F)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France.

Valérie Vilgrain (V)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France; Université de Paris, Faculté de Médecine & INSERM U1149 "centre de recherche sur l'inflammation", CRI, F-75018 Paris, France.

Marco Dioguardi Burgio (M)

Department of Radiology, AP-HP.Nord, Hôpital Beaujon, 92110 Clichy, France; Université de Paris, Faculté de Médecine & INSERM U1149 "centre de recherche sur l'inflammation", CRI, F-75018 Paris, France. Electronic address: marco.dioguardiburgio@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH